Improved quality of life is the way to longer life
Menée dans le cadre de l'essai ChekMate 025 sur 706 patients atteints d'un carcinome rénal de stade avancé, cette étude analyse la qualité de vie liée à la santé des patients en fonction du traitement reçu (nivolumab ou évérolimus)
In The Lancet Oncology, David Cella and colleagues report the quality-of-life results from the previously published Checkmate 025 trial. The original study, which included patients with advanced renal cell carcinoma previously treated with antiangiogenic therapies, showed that nivolumab was superior to everolimus in terms of overall survival (the primary endpoint of the study), proportion of patients achieving an objective response, tolerability, and quality of life. No differences in progression-free survival were detected.
The Lancet Oncology 2016